

## **ROLE OF TOCOLYTICS IN PRETERM**

### **Abstract :**

Tocolytics are the drugs that are used to prolong the time of child birth, for a short period - up to 2 days. If the labour starts too early during pregnancy also termed as preterm birth, which is supposed to be one of the major cause of neonatal mortality and morbidity, all over the world. Administration of tocolytic agents can help in preterm labour to delay the preterm labour by 48 hours. Tocolytics temporarily slow the contractions and hence it is possible to transport the patient to a hospital, where specialized care can be provided to premature baby and also corticosteroids can be administered, which help mature the baby's lungs. Different class of drugs are studied as tocolytics. Beta-Adrenergic receptor agonists like Terbutaline, Ritodrine, Fenoterol, Metaproterenol, Hexoprenaline, Albuterol, Orciprenaline, Nylidrin. Calcium channel blockers like Nifedipine and Nifedipine. Magnesium Sulfate. Nonsteroidal antiinflammatories or prostaglandin inhibitors like Indomethacin, and Oxytocin inhibitors like Atosiban were found effective in different studies with some side effects, are discussed here briefly. Some Nitrates, alcohol, Progesterone have also been tried with not much significant effect. Calcium channel blocker specially Nifedipine is most studied and found to be safer and effective for tocolysis. Individual uterine relaxant therapy should take into account individual differences in metabolism and response to drugs.. Short term use of tocolytics has been proven more effective and safer than longer use of it for pre-term labour.

**Keywords** – tocolytics, preterm labor, tocolysis, Nifedipine, preterm birth

### **Introduction**

Preterm birth is still a major problem faced by Gynaecologists and obstetricians all over the world. Preterm is defined as babies born alive before the completion of 37 weeks of gestation or less than 259 days of gestation by World Health Organization (WHO)<sup>1</sup>. The reason for preterm labour is still not clear. It could be because of premature activation of the contraction of uterine muscles due to physiological or pathological factors. Uterine distension is due to multiple pregnancies, placental ischemia, cervicitis, immune and allergic phenomena, placental abruption or residual bleeding, intrauterine infections, and other complications. Inflammatory process may be the cause of preterm labour.

According to the WHO report, it is estimated that every year around the world there are about 15 million premature births. This number can be counted as more than 1 in 10 live births. About 1 million babies die due to complications arising from premature birth, every year.<sup>2</sup>.In

India, a total of 27 million preterm births take place every year, out of which 3.5 million are born preterm or may qualify as preterm labor<sup>3</sup>. Premature birth is supposed to be one of the major causes of infant mortality and morbidity.

Tocolytics are the drugs that are used to prolong the time of child birth for a short period - up to 2 days<sup>4</sup>. Tocolytics temporarily slow the contractions and hence it is possible to transport the patient to a hospital, where specialized care can be provided to premature baby and also corticosteroids or antibiotics can be administered<sup>5</sup>.

Recommended treatments for preterm labour can help stop or delay the contractions at the time of labour and prevent the future health problems for both mother and baby. By reducing the uterine contractions, placental blood flow can be improved thereby the oxygen supply to the foetus can be improved. Prenatal corticosteroid has clearly showed that it is useful in reducing infant multiple morbidity and mortality<sup>6</sup>. Antenatal corticosteroids like betamethasone and dexamethasone can be administered to speed up the development of baby's lung. The chances of having major health problems after birth like, problems of respiratory system - respiratory distress syndrome, intraventricular haemorrhage, necrotizing enterocolitis and various bacterial infections can be reduced only if preterm is delayed.

The purpose of this review is to take a look on currently used tocolytic drugs and putting forward the evidence showing their effectiveness in prolonging pregnancy by short period of time of at least 2 days.

### **Mechanisms of Tocolysis**

The average gestational age of women starting labour is 40 weeks. In case of preterm labour, uterine contractions start due to change in the equilibrium of proinflammatory and anti-inflammatory cytokines<sup>7</sup>. Tocolysis focuses on delaying uterine contractions and making them weak. The myometrium, the smooth muscles in the uterus are responsible for the contractions of uterus. Contraction of myometrium can be explained as a process, which is complex and based on the functions of myocytes, the special muscle cells. It is associated with the hormonal receptors, intercellular gap junctions, ions channels. The regulatory increase in the intracellular calcium concentration is an important factor for the smooth muscle contraction of the uterus<sup>9</sup>. The initiation of the contractions is not a result of any hormonal stimulus or any kind of nerve input. The contractions begin with a impulsive depolarization of the cells, which in turn opens the calcium channels<sup>10</sup>.

The smooth muscle cells or uterine myocytes, which contain many dense bodies, dense bands and myofilaments. The actin filaments of dense bodies attach to each other, thereby forcibly making the uterine contractions along the lengthwise direction of the cell. The contractile apparatus containing actin filaments connect to the cytoskeleton to form the dense bands. The result is the transmission of force from the contractile muscles to the plasma membrane resulting in condensing of the muscles of cytoskeleton. Beta-adrenergic receptor agonists, nitric oxide donors, magnesium sulfate, and ca channel blockers interfere with the intracellular messenger responsible for the effects of uterine muscle contraction and relaxation proteins. In addition, the oxytocin receptor antagonist, Atosiban and prostaglandin synthetase inhibitors interfere with endogenous stimulants in the uterus to inhibit the synthesis of contractile factors. They are the most commonly used antipyretics today.

### **Types of Tocolytic Treatment**

[1] Beta-Adrenergic receptor agonists:

The most common Beta-Adrenergic receptor agonists are terbutaline, ritodrine, albuterol, fenoterol, hexoprenaline, metaproterenol, nylidrin, and orciprenaline<sup>11</sup>. All of these are selective beta 2 agonists. Ritodrine and salbutamol were used regularly for preterm labour in 1980.

During acute phase, they are administered by IV infusion. For prophylactic therapy, they are given orally.

A scientist divided the adrenergic receptors into alpha- and beta-adrenergic receptors which are placed on the cell membrane. All adrenergic receptors are coupled with G-protein receptors which help in regulating the production of intracellular second messengers.

Betamimetics exert a stimulant effect on beta-2 receptors. When cyclic AMP is increased cyclically, the intracellular ca levels are depleted, reducing the contractility of the uterine muscles. As per many studies, beta-2 adrenergic receptor agonists are known for causing adverse effects in mother. They are dyspnoea, tachycardia, chest pain, hyperglycaemia and hypokalaemia<sup>12</sup>.

Tremor is due to stimulation of beta 2 receptors of skeletal muscle. Tolerance develops to this effect on continued administration. Tachycardia and palpitation are due to stimulation of beta 1 receptors of heart. Hyperglycaemia may occur in diabetic following parenteral administration of beta 2 agonists. Hypokalaemia is due to shift of k<sup>+</sup> not cells. So, though they are efficient, the wellbeing of mother and child is one of the real troubles which is responsible for discontinuation of therapy.

## [2] Ca channel blockers

They work on T-type ca channels and the entry of calcium into the smooth muscle of uterus is inhibited<sup>13</sup>. Dihydropyridine ca channel blockers, for example nifedipine and nifedipine, act on L-type ca channels and inhibit the ca inflow into myocytes of uterus. The decreased intracellular ca concentration arrest the renevation of the myosin chain kinase, and thus uterine muscle contraction is prevented or impaired.

The most studied ca channel blocker is nifedipine and many analysis are in support of its effectiveness as far as acute tocolysis is concerned. A recent study, which included 26 studies and involved 2,179 women, found that there is no major difference between the tocolytic, nifedipine and other tocolytics in delaying delivery by up to 2 days<sup>14</sup>. The study stated, nifedipine showed to have fewer maternal adverse effects than other analgesics. A recent network analysis and another decision study showed that ca channel blockers would be the best choice antipyretic as far as preterm labour is concerned<sup>15</sup>. It is given orally.

## [3] Magnesium sulfate

It is supposed to be the safest tocolytic therapy since 1971<sup>16</sup>. Calcium antagonism present in the motor terminal layer, arrest the release of acetylcholine and the transfer of stimuli. Ca interference at the membrane of plasma arrests its intracellular flow and the myosin kinase chain required for uterine muscle contraction is activated. It has a depressant effect on the uterine smooth muscle, central nervous system and myocardium. It is used to control convulsions and BP in toxemia of pregnancy. It is useful when beta 2 agonists are contraindicated.

Magnesium sulfate is supposed to be given IV to achieve normal levels. Initially a heavy dose of 4-6 g in 10-20% solution over half an hour is given, followed by dose of 2 g every hour<sup>17</sup>.

The adverse effects of magnesium sulfate treatment on maternal health can be like, flushing and somnolence to major symptoms like, cardiac arrhythmias and respiratory depression.

#### [4] Oxytocin receptor blockers

A selective oxytocin or vasopressin, Atosiban receptor antagonist, works by reducing intracellular calcium and thereby inhibiting uterine contractions<sup>18</sup>. This is done by blocking oxytocin receptors and the preventing the transformation of phosphatidylinositol to inositol triphosphate. Ca is released in the protoplasm, in this process.

An intravenous agent, Atosiban is given 6.75 mg bolus over one minute, IV followed by a continuous infusion at 18 mg/hour for continuous 3 hours, then 6 mg/hour for up to 45 hours<sup>19</sup>. Atosiban showed rare and non-life threatening adverse effects on maternal health and the only reactions were hypersensitivity.

A Cochrane review of 6 trials involving 1695 patients studied with Atosiban did not show superiority in terms of efficacy as far as lipolysis or neonatal outcomes is concerned<sup>20</sup>.

#### [5] Prostaglandin inhibitors

Indomethacin is a prostaglandin inhibitor widely used to delay preterm labor<sup>21</sup>. Prostaglandins are endocrine hormones acting and influencing the contraction of the uterine muscles and forming the junctions of uterine muscle gap. They are responsible for the free intracellular ca concentration and activate of the myosin chain kinase.

Usually, indomethacin is given orally as a heavy dose of 50 mg, followed by 25 to 50 mg orally every four times a day for up to 2 days. Due to the adverse effects, its use is limited in pre mature labour with normal amniotic fluid levels and normal kidney function.<sup>22</sup>

A recent study showed that prostaglandin inhibitors were more effective in prolonging delivery for 2 days. In addition, prostaglandin inhibitors showed more benefit than any other antipyretic and had a 95% chance of being ranked in first 3 useful known antipyretics, used.<sup>23</sup>

#### [6] Nitrates and other drugs

Alcohol was used as tocolytic agent in 1970<sup>22</sup>. But the bad effect on maternal health and infant were more as compared to any benefits.

Nitric Oxide is a powerful vasodilator. It is synthesized in an oxidation of amino acids. It is present in the cells of the uterine muscle and there is a connection between the production of nitric oxide and relaxation of uterus.

The transdermal nitroglycerin was used in preterm labour, but the absence of large randomized studies has made its use limited. Nitrate drugs have been used based on animal studies confirming that activity correlates with work. But studies in humans show opposite results. A recent network study determined that nitrates had only a 5% chance of being the best agent for delaying labour by 2 days and a 11% chance of being the good agent for reducing maternal adverse events<sup>23</sup>.

#### [7] Progesterone

Progesterone is described as a steroid hormone, which is secreted after the completion of 8 weeks of pregnancy, by the corpus luteum and placenta. It shows effects on the intracellular  $Ca^{2+}$  concentration and the synthesis of prostaglandins. The Progesterone therapy is used commonly as a preventive strategy. It is found helpful in reducing pre mature births in certain high-risk populations<sup>24</sup>. However, not many trials have suggested that the use of progesterone for acute tocolysis, is useful. These studies showed several problems, including their use with other tocolytics. Studies also often don't report delivery times of 48 hours. Therefore, the Cochrane review of the topic did not find sufficient evidence to support pregnancy-inducing agents as tocogenic agents<sup>25</sup>.

#### [8] Antibiotics

Bacterial infection is one of the causes of pre mature labour but usually before 30 weeks. The antibiotics used to prevent the pre mature labour have been studied and it is generally not recommended because of only small evidence of benefit<sup>26</sup>. But in cases of premature rupture of membranes, a analysis of 22 studies, which was conducted on approximately 6000 patients, showed a significant reduction in the number of premature births and reduction in complications in infants in the treated group<sup>27</sup>. Tocolytic tests typically utilize drug from above mentioned drugs. Beside this, study on other drugs is limited in the field of tocolysis. Ifenprodil, when used in a small trial in France, it was not found to be as effective as ritodrine<sup>28-33</sup>.

#### [9] Other drugs

Halothane, a fluorinated inhalational anaesthetic, has a potent tocolytic effect. Some studies state that it is still not clear about its use in pregnancy. Whether its use will cause any harm to the foetus is the question and hence it is very rarely used as tocolytic.

### **Discussion:**

Many interventions are possible in treating the problems or in delaying the pre mature delivery. As mentioned above not all the drugs are proved efficient. Though some drugs showed proven efficacy on the contraction of the uterus, there is no confirmation on the improvement in neonatal outcome.

Single drug is used in some cases and combined therapy is observed in many cases. The data is still not sufficient to decide, which drug should be given and at what stage.

In a pregnant woman with history of multiple pregnancies, atosiban showed better results as compared to drugs like  $Ca^{2+}$  channel blocker or magnesium sulphate. Also in the cases of anaemia, again atosiban showed better results as compared to beta adrenergic receptor agonists. Atosiban showed less adverse effects than other tocolytics. Beta adrenergic receptor can cause foetal tachycardia. Indomethacin can be held responsible for renal dysfunction. The foetal right ventricular function is seen depressed due to magnesium sulphate. The reason for all above adverse effects can be stated as these drugs traverse the placenta quickly but their excretion is slower by the kidneys of the foetus as compared to the kidneys of the mother.

Hence, it is very important during the premature delivery, to choose a tocolytic drug which is safe as well as effective and at the same time, it should be patient specific.

General considerations while using tocolytic or any other drugs in pregnancy (pharmacological):

When choosing a tocolytic or any other drug, the characteristics of the patient should be taken into account. Individualized lipolysis is essential, and metabolism differences in different pregnant women and response for the drug in individual patients should be taken into consideration. Pregnancy is also known to change the disposal of medicine. In a pregnant woman who is otherwise healthy, the clearance of creatinine is seen increased by 1.5-fold times<sup>29</sup>. This in turn will increase the clearance of many drugs like magnesium. Comorbidities should also be taken into consideration, while choosing tocolytic therapy. For example, in pregnant women with impaired kidney function, magnesium and indomethacin should not be used.

Tocolytic medications should not be used in women when the following complications are observed in pregnant women:

Eclampsia – increase in blood pressure beyond the normal limits, during pregnancy or

Severe preeclampsia

Hemorrhage or severe bleeding

Chorioamnionitis or any kind of womb infection

Also if there is some kind of abnormality detected in the foetus that could lead to the death of baby after the delivery or if the foetus is not live.

But, tocolytic medications are advised by the doctors in the following conditions as the benefits will definitely exceed the risks for both the mother and child.

Dilated cervix – More than 4 centimetres

Mild preeclampsia

Stable and mild bleeding during the third trimester

Also when, the baby shows an abnormal heart rate on the foetal heart monitor.

### **Conclusion:**

Using Tocolytics for a Short period is common procedure to prolong pregnancy, so as it allows transportation of the mother to the hospital nearby or the tertiary care centre and to start therapies for growth and well-being of the foetus. Tocolytics were used in some trials for long periods, but they failed to demonstrate major benefits. Various types of tocolytics were used in different studies. Although the choice of which agent should be used first is not clear, it is clear that short-term tocolytic is an effective and useful therapy for women with pre mature labour. These could give us insight into the future of obstetric therapy and further personalize drug treatment during pregnancy.

### **References:**

1. C. Hubinont<sup>1</sup> and F. Debieve, Prevention and Management of Preterm Birth, Review Article : 2011 Update on Tocolysis, Volume 2011 |Article ID 941057 |

2. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. *Lancet*. 2016;388(10063):3027-35.
3. Kishore Kumar, World Health Day 2019: Is India's Healthcare System Failing Premature Babies?, Apr 07, 2019 12:32:45 Ist
4. Christopher Mayer; Irasema Apodaca-Ramos, Tocolysis, StatPearls [Internet], Last Update: September 9, 2021
5. Mayer, Christopher; Apodaca-Ramos, Irasema (2021), "Tocolysis", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32965883, retrieved 29 July 2021
6. Crowley P. Prophylactic corticosteroids for preterm birth. *Cochrane Database Syst Rev*. 2000;2:CD000065. [PubMed] [Google Scholar]
7. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. *Science*. 2014 Aug 15;345(6198):760-5. [PMC free article] [PubMed]
8. R. C. Young, "Myocytes, myometrium, and uterine contractions," *Annals of the New York Academy of Sciences*, vol. 1101, pp. 72–84, 2007., View at: Publisher Site | Google Scholar
9. A. L. Bernal, "The regulation of uterine relaxation," *Seminars in Cell and Developmental Biology*, vol. 18, no. 3, pp. 340–347, 2007, View at: Publisher Site | Google Scholar
10. Wray S, Prendergast C. The Myometrium: From Excitation to Contractions and Labour. *Adv Exp Med Biol*. 2019;1124:233-263. [PubMed]
11. A. L. Bernal, "The regulation of uterine relaxation," *Seminars in Cell and Developmental Biology*, vol. 18, no. 3, pp. 340–347, 2007.
12. S. Caritis, "Adverse effects of tocolytic therapy," *British Journal of Obstetrics and Gynaecology*, vol. 112, supplement 1, pp. 74–78, 2005.
13. Cretoiu SM, Radu BM, Banciu A, Banciu DD, Cretoiu D, Ceafalan LC, Popescu LM. Isolated human uterine telocytes: immunocytochemistry and electrophysiology of T-type calcium channels. *Histochem Cell Biol*. 2015 Jan;143(1):83-94. [PMC free article] [PubMed]
14. A. Conde-Agudelo, R. Romero, and J. P. Kusanovic, "Nifedipine in the management of preterm labor: a systematic review and metaanalysis," *American Journal of Obstetrics and Gynecology*, vol. 204, no. 2, pp. 134.e1–134.e20, 2011
15. Hanley M, Sayres L, Reiff ES, Wood A, Grotegut CA, Kuller JA. Tocolysis: A Review of the Literature. *ObstetGynecolSurv*. 2019 Jan;74(1):50-55. [PubMed]
16. Steer CM, Petrie RH. A comparison of magnesium sulfate and alcohol for the prevention of premature labor. *Am J Obstet Gynecol*. 1977;129(1):1–4. [PubMed] [Google Scholar]
17. Elliott JP. Magnesium sulfate as a tocolytic agent. *Am J Obstet Gynecol*. 1983;147(3):277–284. [PubMed] [Google Scholar]
18. Saade GR, Shennan A, Beach KJ, Hadar E, Parilla BV, Snidow J, Powell M, Montague TH, Liu F, Komatsu Y, McKain L, Thornton S. Randomized Trials of Retosiban Versus Placebo or Atosiban in Spontaneous Preterm Labor. *Am J Perinatol*. 2021 Aug;38(S 01):e309-e317. [PubMed]
19. Worldwide Atosiban versus Beta-agonists Study Group, Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. *BJOG*. 2001;108(2):133–142. [PubMed] [Google Scholar]
20. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. *Cochrane Database Syst Rev*. 2005;3:CD004452. [PubMed] [Google Scholar]

21. Worldwide Atosiban Versus Betaagonists Study Group, "Effectiveness and safety of the oxytocin antagonist atosiban versus beta adrenergic agonists in the treatment of preterm labour," *British Journal of Obstetrics and Gynaecology*, vol. 108, no. 2, pp. 133–142, 2001
22. David M Haas, Tara Benjamin, Renata Sawyer, and Sara K Quinney, Short-term tocolytics for preterm delivery – current perspectives, *Int J Womens Health*. 2014; 6: 343–349.
23. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. *BMJ*. 2012;345:e6226. [PMC free article] [PubMed] [Google Scholar]
24. Committee on Practice Bulletins-Obstetrics, The American College of Obstetricians and Gynecologists Practice bulletin no 130: prediction and prevention of preterm birth. *Obstet Gynecol*. 2012;120(4):964–973. [PubMed] [Google Scholar]
25. Su LL, Samuel M, Chong YS. Progestational agents for treating threatened or established preterm labour. *Cochrane Database Syst Rev*. 2010;1:CD006770. [PubMed] [Google Scholar]
26. J. King and V. Flenady, "Prophylactic antibiotics for inhibiting preterm labour with intact membranes," *Cochrane Database of Systematic Reviews*, no. 4, article CD000246, 2002.
27. S. Kenyon, M. Boulvain, and J. Neilson, "Antibiotics for preterm rupture of membranes," *Cochrane Database of Systematic Reviews*, no. 2, article CD001058, 2003.
28. Breart G, Sureau C, Rumeau-Rouquette C. A study of the comparative efficiency of ifenprodil and ritodrine in the treatment of threatened premature labour. *J GynecolObstetBiolReprod (Paris)* 1979;8(3):261–263. French. [PubMed] [Google Scholar]
29. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. *Clin Pharmacokinet*. 2012;51(6):365–396. [PubMed]
30. Patil, Bhakti, and Aruna Chandak. "Comparative Study of 0.2% Ropivacaine & 0.2% Ropivacaine with 0.5 Mcg/ML Dexmedetomidine in Epidural Labour Analgesia." *JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS* 9, no. 13 (March 30, 2020): 1091–96. <https://doi.org/10.14260/jemds/2020/235>.
31. Shelke, Uttara, and Deepti Srivastava. "PREDICTION OF MODE OF DELIVERY BY ANGLE OF PROGRESSION BEFORE THE ONSET OF LABOUR IN FULL TERM GRAVID WOMEN." *INTERNATIONAL JOURNAL OF MODERN AGRICULTURE* 9, no. 3 (2020): 86–89.
32. Agarwal H, Acharya N, Shrivastava D, Mohammad S. Pregnancy with Uterine Prolapse - Rare Cases with Distinct Labour Outcomes. *JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS*. 2021 Feb 1;10(5):329–32.
33. Wanjari S, Wanjari A. Labour Induction Methods: An Overview. *JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL*. 2021;33(37A):119–27.